MuseCell Innovations
The MCI Scientific Record

The published evidence on Authentic Dezawa MuseCells®

A searchable record of the peer-reviewed literature on Muse cells — indexed by tier, indication, and mechanism.

178 PEER-REVIEWED RECORDS

Cornerstone · 24 records

Highlighted · 34 records

Untiered · 120 records



The Programme · Continuing

Clinical pipeline

Six published Phase 1/2 readouts from the LSI / CL2020 era form the completed human-evidence base. Five additional MCI trials are advancing across the US, UAE, and Germany. The Dezawa MuseCells® platform is one continuous research line, still moving.

6Published Phase 1/2 readouts
5Active trials in preparation
Newly Registered · ClinicalTrials.gov ● Recruiting

Registry of Outcomes of Dezawa MuseCells®

A prospective, multi-year observational registry — tracking real-world clinical outcomes after authentic Dezawa MuseCells® administration across osteoarthritis, orthopaedic, pain, wound-care, and longevity indications, with a 5,000-participant target and five-year follow-up.

NCT07645989  ·  Observational registry  ·  Sites: BioReset Medical (FL) & Regene Labs (MX)  ·  View on ClinicalTrials.gov →
Zone A · Historical — LSI / CL2020 era · 2018–2023 · completed human evidence base
IndicationPreclinicalPhase 1Phase 2Phase 2b / 3Status
MCISubacute Ischemic StrokeCompleteNiizuma 2023PMID 37756573 · RCT n=35Phase 2 readout published
MCIAcute Myocardial InfarctionCompleteNoda 2020Circ J · n=3 FIHPhase 1 readout published
MCIAmyotrophic Lateral SclerosisCompleteYamashita 2023PMID 38014622 · n=5, 6 dosesPhase 2 readout published
MCICervical Spinal Cord InjuryCompleteKoda 2024PMID 39135172 · n=10 single-dosePhase 1 readout published
MCIEpidermolysis BullosaCompleteFujita 2021PMID 33656198 · Phase 1/2 open-labelPhase 1/2 readout published
MCINeonatal Hypoxic-Ischemic EncephalopathyCompleteSato 2024 (SHIELD)NCT04261335 · n=9 dose-escalationPhase 1 readout published
Zone B · Active preparation — MCI · 2025–2026 · five trials advancing
IndicationSponsorPrincipal Investigator / PartnerLocationPhaseStage
MCIAesthetic · facialMCIDr. LaykeDMC injectionUSAIRB granted · recruiting
MCIShoulder Osteoarthritis · intra-articularMCIFloridaIRB in preparation
MCIKnee OsteoarthritisRCTMCIDr. Jeff WiegersFloridaEnrollment starting September
MCIUAE Multi-IndicationMCICleveland Clinic principal investigatorsAbu Dhabi, UAE1/2
MCICardiovascular, Metabolic & Orthopaedic HealthMCIDeutsches Zentrum für ZelltherapieGerman Center for Cell TherapyGermanyIRB in preparation

The LSI / CL2020 trials were conducted by Life Science Institute, Inc. (a Mitsubishi Chemical Group subsidiary) between 2018–2023; Mitsubishi discontinued the CL2020 program in February 2023 as a corporate-strategy decision unrelated to safety or efficacy. Published results remain valid and form the human-evidence base of the Dezawa MuseCells® lineage. Claims are based on published studies of authentic Dezawa MuseCells®; only cells originating from MCI's manufacturing ecosystem carry the safety and clinical characteristics reported.